Oryzogen Recombinant HSA From Rice Grain Has Good Batch Consistency 70024-90-7

Recombinant human serum albumin HSA from rice grain has good batch consistency

Quick Details

1. Source: Rice Grain (Oryza Sativa)
2. CAS No.: 70024-90-7
3. Purity: Greater than 99 % as determined by SDS-PAGE
4. Physical Appearance: Off-white to light beige lyophilized powder
5. Other Names: Recombinant HSA, rHSA, OsrHSA
6. Formulation: No stabilizer or surface active agent
7. Storage and Handling: Stored at temperatures 2-8℃ for 48 months

Description

Human serum albumin (HSA) is a soluble, globular, and unglycosylated monomeric protein; it functions primarily as a carrier protein for steroids, fatty acids, and thyroid hormones, and plays an important role in stabilizing extracellular fluid volume. HSA is widely used clinically to treat serious burn injuries, hemorrhagic shock, hypoproteinemia, fetal erythroblastosis, and ascites caused by cirrhosis of the liver.

Human serum albumin is derived from human plasma, which is collected from different human bodies. So we can not guarantee the stability of human serum albumin from different batches. Because of this, it is difficult to apply to large-scale application in vaccine production and cell culture. However, Healthgen Biotech uses State-of-the-art platform, having high capacity to express proteins and peptides in the rice grain. The platform uses rice endosperm cells as a bioreactor to specifically and highly express various recombinant proteins and small peptides. By using homozygous rice as the raw material, with the world's top production process, Healthgen Biotech can maximize the stability of albumin batches to meet the needs of industrial production.

Healthgen Biotech recombinant human serum albumin (OsrHSA) has excellent batch consistency. Using self-pollination rice as the bioreactor to express the OsrHSA, with the world's advanced facility and top production proceeding to extract and purify the OsrHSA, Healthgen Biotech can ensure the excellent consistency of rHSA from different batches.

Physiological and Biochemical Properties of rHSA and pHSA

Supplemental Description

Healthgen Biotech, always pay great attention to the original technological innovation and intellectual property protection, has the titles of “Hubei Province Molecular Pharmaceutical Engineering Research Center” and “Protein Purification Research Center”. The rice endosperm cell high expression technology platform and other core technology have applied and gained 13 domestic and international patents; and won the “2012 Hubei Provincial Science and technology invention Award”, “2013 National Science and Technology Invention Award and China Patent Excellence Award’. The project obtained the funding from the National Ministry of science and high technology “863 plan”, Major national science and technology plan “Major projects of new varieties of genetically modified organisms” and “Major projects for new drug discovery”, the National Development and Reform Commission “Pilot development of strategic emerging industries”, National Ministry of science and technology innovation fund and state and local plans for all kinds of talented people funding. In July 2015, Healthgen Biotech became a public company on the "China New OTCBB", a national share transfer system for SMEs and officially known as the National Equities Exchange and Quotations, which is the “first stock” of the plant-derived pharmaceutical in China and even the world.